May T - Search Results

1

The VIRGO study: nevirapine, didanosine and stavudine combination therapy in antiretroviral-naive HIV-1-infected adults.

Raffi F, Reliquet V, Ferré V, Arvieux C, Hascoet C, Bellein V, Besnier JM, Breux JP, Garré M, May T, Molina JM, Perré P, Raguin G, Rozenbaum W, Zucman D. Raffi F, et al. Among authors: may t. Antivir Ther. 2000 Dec;5(4):267-72. Antivir Ther. 2000. PMID: 11142621 Clinical Trial.

2

[Mycobacterium avium complex disease in HIV seropositive patients: incidence and risk factors before and after the introduction of highly active antiretroviral treatments. Clinical Epidemiology Group of the Information and Care Center for Human Immunodeficiency].

Mary-Krause M, Rabaud C, Jouan M, Obadia M, de la Blanchardière A, Raffi F, May T. Mary-Krause M, et al. Among authors: may t. Pathol Biol (Paris). 2000 Jun;48(5):495-504. Pathol Biol (Paris). 2000. PMID: 10949848 French.

3

Progression to AIDS or death as endpoints in HIV clinical trials.

Raffi F, Chêne G, Lassalle R, May T, Billaud E, Fleury H, Dellamonica P, Leport C; APROCO Study Group. Anti-protease cohort. Raffi F, et al. Among authors: may t. HIV Clin Trials. 2001 Jul-Aug;2(4):330-5. doi: 10.1310/Q2L2-QVRK-4E01-C8F8. HIV Clin Trials. 2001. PMID: 11590536

4

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

Chêne G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, May T, Journot V, Raffi F, Jarrousse B, Grappin M, Lepeu G, Molina JM. Chêne G, et al. Among authors: may t. Clin Infect Dis. 2002 Mar 1;34(5):649-57. doi: 10.1086/338811. Epub 2002 Jan 24. Clin Infect Dis. 2002. PMID: 11810598 Clinical Trial.

5

Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.

Duval X, Journot V, Leport C, Chêne G, Dupon M, Cuzin L, May T, Morlat P, Waldner A, Salamon R, Raffi F; Antiprotease Cohort (APROCO) Study Group. Duval X, et al. Among authors: may t. Clin Infect Dis. 2004 Jul 15;39(2):248-55. doi: 10.1086/422141. Epub 2004 Jul 1. Clin Infect Dis. 2004. PMID: 15307035

6

Long-term assessment of nevirapine-containing highly active antiretroviral therapy in antiretroviral-naive HIV-infected patients: 3-year follow-up of the VIRGO study.

Reliquet V, Allavena C, François-Brunet C, Perré P, Bellein V, Garré M, May T, Souala F, Besnier JM, Raffi F. Reliquet V, et al. Among authors: may t. HIV Med. 2006 Oct;7(7):431-6. doi: 10.1111/j.1468-1293.2006.00402.x. HIV Med. 2006. PMID: 16925728 Free article. Clinical Trial.

7

Intermittent antiretroviral therapy in patients with controlled HIV infection.

Marchou B, Tangre P, Charreau I, Izopet J, Girard PM, May T, Ragnaud JM, Aboulker JP, Molina JM; ANRS 106 Study team. Marchou B, et al. Among authors: may t. AIDS. 2007 Feb 19;21(4):457-66. doi: 10.1097/QAD.0b013e328013d9eb. AIDS. 2007. PMID: 17301564 Clinical Trial.

8

Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial).

Molina JM, Journot V, Furco A, Palmer P, De Castro N, Raffi F, Morlat P, May T, Rancinan C, Chêne G; Montana (ANRS 091) Study Group. Molina JM, et al. Among authors: may t. Antivir Ther. 2007;12(3):417-22. Antivir Ther. 2007. PMID: 17591032 Clinical Trial.

9

Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy.

Grabar S, Lanoy E, Allavena C, Mary-Krause M, Bentata M, Fischer P, Mahamat A, Rabaud C, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Grabar S, et al. HIV Med. 2008 Apr;9(4):246-56. doi: 10.1111/j.1468-1293.2008.00554.x. HIV Med. 2008. PMID: 18366449 Free article.

10

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

Roquebert B, Damond F, Collin G, Matheron S, Peytavin G, Bénard A, Campa P, Chêne G, Brun-Vézinet F, Descamps D; French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2). Roquebert B, et al. J Antimicrob Chemother. 2008 Nov;62(5):914-20. doi: 10.1093/jac/dkn335. Epub 2008 Aug 20. J Antimicrob Chemother. 2008. PMID: 18718922

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,219 results

Search Page